Quantcast

Zarxio, a Cheaper Alternative to Neupogen


#1

The FDA just approved zarxio, a biosimilar to neupogen:

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm

It is expected to be much cheaper than neupogen. Usually though, oncologists tend to prescribe neulasta which is a version of neupogen that stays longer in the body. So the nest question is whether zarxio's manufacturer has a similar version of zarxio to offer...